𝔖 Bobbio Scriptorium

✦ LIBER ✦

Efficacy and safety results of secukinumab, a fully human monoclonal anti-interleukin-17a antibody, in the treatment of moderate-to-severe plaque psoriasis: A phase II regimen-finding trial

Book ID: 116589010
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 47 KB
Volume: 66
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2011.11.804

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and Efficacy of ABT-874, a Fully

Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis

✍ Kimball, Alexa B. 📂 Article 📅 2008 🏛 American Medical Association 🌐 English ⚖ 157 KB

Effect of secukinumab, a fully human ant

Effect of secukinumab, a fully human anti–interleukin-17a monoclonal antibody on C-reactive protein levels in patients with moderate to severe plaque psoriasis: Result of a dose-ranging study

📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Efficacy and safety of secukinumab, a fu

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

✍ McInnes, I. B.; Sieper, J.; Braun, J.; Emery, P.; van der Heijde, D.; Isaacs, J. 📂 Article 📅 2013 🏛 BMJ Publishing Group 🌐 English ⚖ 471 KB

Secukinumab efficacy in moderate to seve

Secukinumab efficacy in moderate to severe psoriasis appears not to be affected by previous biologic use: Results of a phase II, regimen-finding trial

📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Secukinumab efficacy and safety in subje

Secukinumab efficacy and safety in subjects with moderate to severe plaque psoriasis: Results from the Judging the efficacy of secUkinumab in patients with psoriasis using autoiNjector: a Clinical Trial evalUating treatment REsults trial (JUNCTURE)

📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Retreatment efficacy and long-term safet

Retreatment efficacy and long-term safety of the fully human, interleukin -12/-23 monoclonal antibody ABT-874 in the treatment of moderate to severe psoriasis: 48-week results from a phase II trial

📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB